drugset / Trial / NCT01870999

A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot

NCT01870999

RandomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the safety, tolerability, efficacy and pharmacokinetics of aripiprazole intramuscular (IM) depot multiple doses every 4 weeks in adult patients with schizophrenia.

Timeline

Start
2007-11
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified 10 mg Intramuscular
Subject Aripiprazole Other / unclassified 200 mg Intramuscular
Subject Aripiprazole Other / unclassified 300 mg Intramuscular
Subject Aripiprazole Other / unclassified 400 mg Intramuscular

Indications